Skin manifestations in lupus erythematosus. Clinical aspects and therapy;Hautmanifestationen des lupus erythematodes. Klinik und Therapie

Zeitschrift fur Rheumatologie

Volumn 70, Issue 3, 2011, Pages 213-227

  Kuhn, A ^a   Ruland, V ^a   Bonsmann, G ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Antimalarials; Cutanous (CLE); Histology; Lupus erythematosus; Systemic (SLE); Therapy

Indexed keywords

ANTIMALARIAL AGENT; CALCINEURIN INHIBITOR; GLUCOCORTICOID; SUNSCREEN;

ARTICLE; HISTOPATHOLOGY; HUMAN; SKIN DEFECT; SKIN LUPUS ERYTHEMATOSUS; SKIN MANIFESTATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADMINISTRATION, TOPICAL; ANTIMALARIALS; GLUCOCORTICOIDS; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; SUNSCREENING AGENTS;

EID: 79959977311     PISSN: 03401855     EISSN: 14351250     Source Type: Journal    
DOI: 10.1007/s00393-011-0789-3     Document Type: Article

References (49)

1. Gronhagen CM, Gunnarsson I, Svenungsson E et al (2010) Cutaneous manifestations and serological findings in 260 patients with systemic lupus erythematosus. Lupus 19:1187-1194
2. Gilliam JN (1977) The cutaneous signs of lupus erythematosus. Cont Educ Fam Phys 6:34-70
3. Costner MI, Sontheimer RD, Provost TT (2003) Lupus erythematosus. In: Sontheimer RD, Provost TT (Hrsg) Cutaneous Manifestations of Rheumatic Diseases. Williams & Wilkins, Philadelphia,S 15-64.
4. Kuhn A, Ruzicka T (2004) Classification of cutaneous lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T (Hrsg) Cutaneous lupus erythematosus. Springer, Berlin, S 53-58
5. Kuhn A, Sonntag M, Richter-Hintz D et al (2001) Phototesting in lupus erythematosus: a 15-year experience. J Am Acad Dermatol 45:86-95 (Pubitemid 32655700)
6. Kuhn A, Gensch K, Haust M et al (2011) Photoprotective effects of a broad-spectrum sunscreen in ultraviolet- induced cutaneous lupus erythematosus: a randomized, vehiclecontrolled, double-blind study. J Am Acad Dermatol 64:37-48
7. Gallego H, Crutchfield CE 3rd, Lewis EJ et al (1999) Report of an association between discoid lupus erythematosus and smoking. Cutis 63:231-234
8. Miot HA, Bartoli Miot LD, Haddad GR (2005) Association between discoid lupus erythematosus and cigarette smoking. Dermatology 211:118-122 (Pubitemid 41160246)
9. Kuhn A, Aberer E, Barde C (2009) Leitlinien Kutaner Lupus Erythematosus (Entwicklungsstufe 1). In: Korting HC, Callies R, Reusch M et al (Hrsg) Dermatologische Qualitätssicherung: Leitlinien und Empfehlungen. ABW Wissenschaftsverlag GmbH, Berlin, S 214-257
10. Yoshimasu T, Hiroi A, Uede K et al (2001) Discoid lupus erythematosus (DLE)-like lesion induced by uraciltegafur (UFT). Eur J Dermatol 11:54-57 (Pubitemid 32150382)
11. Jimenez S, Cervera R, Ingelmo M et al (2004) The epidemiology of cutaneous lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T (Hrsg) Cutaneous lupus erythematosus. Springer, Berlin, S 45-52
12. Popovic K, Nyberg F, Wahren-Herlenius M (2007) A serology-based approach combined with clinical examination of 125 Ro/SSA-positive patients to define incidence and prevalence of subacute cutaneous lupus erythematosus. Arthritis Rheum 56:255-264 (Pubitemid 46106199)
13. Sontheimer RD (2005) Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev 4:253-263 (Pubitemid 40884542)
14. Kuhn A, Richter-Hintz D, Oslislo C et al (2000) Lupus erythematosus tumidus - a neglected subset of cutaneous lupus erythematosus: report of 40 cases. Arch Dermatol 136:1033-1041 (Pubitemid 30629131)
15. Tebbe B, Orfanos CE (1997) Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Lupus 6:96-104 (Pubitemid 27102036)
16. Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277 (Pubitemid 13221242)
17. Albrecht J, Berlin JA, Braverman IM et al (2004) Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus. Lupus 13:839-849 (Pubitemid 39551620)
18. Aydogan K, Karadogan S, Balaban Adim S et al (2005) Lupus erythematosus associated with erythema multiforme: report of two cases and review of the literature. J Eur Acad Dermatol Venereol 19:621-627 (Pubitemid 41742848)
19. Ting W, Stone MS, Racila D et al (2004) Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. Lupus 13:941-950 (Pubitemid 39664954)
20. Kuhn A, Bein D, Bonsmann G (2009) The 100th anniversary of lupus erythematosus tumidus. Autoimmun Rev 8:441-448
21. Lee LA (2005) Transient autoimmunity related to maternal autoantibodies: neonatal lupus. Autoimmun Rev 4:207-213 (Pubitemid 40704704)
22. Rein AJ, Mevorach D, Perles Z et al (2009) Early diagnosis and treatment of atrioventricular block in the fetus exposed to maternal anti-SSA/Ro- SSB/La antibodies: a prospective, observational, fetal kinetocardiogrambased study. Circulation 119:1867-1872
23. Silverman E, Jaeggi E (2010) Noncardiac manifestations of neonatal lupus erythematosus. Scand J Immunol 72:223-225
24. Kuhn A, Sonntag M, Ruzicka T et al (2003) Histopathologic findings in lupus erythematosus tumidus: review of 80 patients. J Am Acad Dermatol 48:901-908 (Pubitemid 36706225)
25. Kuhn A, Ruland V, Bonsmann G (2010) Photosensitivity, phototesting, and photoprotection in cutaneous lupus erythematosus. Lupus 19:1036-1046
26. Albrecht J, Taylor L, Berlin JA et al (2005) The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 125:889-894
27. Kuhn A, Meuth AM, Bein D et al (2010) Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol 163:83-92
28. Wahie S, McColl E, Reynolds NJ et al (2010) Measuring disease activity and damage in discoid lupus erythematosus. Br J Dermatol 162:1030-1037
29. Abdel-Aziz K, Goodfield M (2008) Evaluation of the Cutaneous Lupus Activity and Severity Score in the assessment of lupus erythematosus skin disease. Br J Dermatol 158:181-182 (Pubitemid 350221907)
30. Kuhn A, Ruland V, Bonsmann G (2010) Cutaneous lupus erythematosus: Update of therapeutic options Part I. J Am Acad Dermatol [Epub ahead of print]
31. Faurschou A, Wulf HC (2007) The relation between sun protection factor and amount of suncreen applied in vivo. Br J Dermatol 156:716-719 (Pubitemid 46452341)
32. Jessop S, Whitelaw DA, Delamere FM (2009) Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev: CD002954
33. Sardy M, Ruzicka T, Kuhn A (2009) Topical calcineurin inhibitors in cutaneous lupus erythematosus. Arch Dermatol Res 301:93-98
34. Kuhn A, Gensch K, Haust M et al (2011) Efficacy of tacrolimus 0·1% ointment in cutaneous lupus erythematosus - A multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol 2011 (in press)
35. Edwards KR, Burke WA (1999) Treatment of localized discoid lupus erythematosus with tazarotene. J Am Acad Dermatol 41:1049-1050
36. Seiger E, Roland S, Goldman S (1991) Cutaneous lupus treated with topical tretinoin: a case report. Cutis 47:351-355
37. Wulf HC, Ullman S (2007) Discoid and subacute lupus erythematosus treated with 0.5% R-salbutamol cream. Arch Dermatol 143:1589-1590 (Pubitemid 350277785)
38. Jemec GB, Ullman S, Goodfield M et al (2009) A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus. Br J Dermatol 161:1365-1370
39. Ochsendorf FR (2010) Einsatz von Antimalariamitteln in der Dermatologie. J Dtsch Dermatol Ges 8:829-844
40. Wolfe F, Marmor MF (2010) Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res 62:775-784
41. Marmor MF, Kellner U, Lai TY et al (2011) Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 118: 415-422
42. Wallace DJ (1989) The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin Arthritis Rheum 18:282-296
43. Jewell ML, McCauliffe DP (2000) Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 42:983-987 (Pubitemid 30368665)
44. Kuhn A, Ruland V, Bonsmann G (2010) Cutaneous lupus erythematosus: Update of therapeutic options Part II. J Am Acad Dermatol [Epub ahead of print]
45. Wenzel J, Brahler S, Bauer R et al (2005) Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol 153:157-162 (Pubitemid 41044542)
46. Ruzicka T, Sommerburg C, Goerz G et al (1992) Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 127:513-518
47. Appel AS, Appel GB (2009) An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases. Nat Clin Pract Nephrol 5:132-142
48. Pisoni CN, Sanchez FJ, Karim Y et al (2005) Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol 32:1047-1052 (Pubitemid 40828077)
49. Kreuter A, Tomi NS, Weiner SM et al (2007) Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol 156:1321-1327 (Pubitemid 47029802)